Luye Pharma Group Statistics

Total Valuation

Luye Pharma Group has a market cap or net worth of HKD 7.97 billion. The enterprise value is 12.31 billion.

Market Cap	7.97B
Enterprise Value	12.31B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Luye Pharma Group has 3.76 billion shares outstanding. The number of shares has increased by 4.81% in one year.

Current Share Class	n/a
Shares Outstanding	3.76B
Shares Change (YoY)	+4.81%
Shares Change (QoQ)	-0.01%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	28.22%
Float	1.95B

Valuation Ratios

The trailing PE ratio is 9.63 and the forward PE ratio is 9.11. Luye Pharma Group's PEG ratio is 0.48.

PE Ratio	9.63
Forward PE	9.11
PS Ratio	1.18
PB Ratio	0.57
P/TBV Ratio	1.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	0.48

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.74, with an EV/FCF ratio of -94.48.

EV / Earnings	14.87
EV / Sales	1.82
EV / EBITDA	5.74
EV / EBIT	8.91
EV / FCF	-94.48

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.67.

Current Ratio	1.28
Quick Ratio	1.03
Debt / Equity	0.67
Debt / EBITDA	4.74
Debt / FCF	-77.94
Interest Coverage	1.99

Financial Efficiency

Return on equity (ROE) is 6.33% and return on invested capital (ROIC) is 3.52%.

Return on Equity (ROE)	6.33%
Return on Assets (ROA)	3.00%
Return on Capital (ROIC)	3.52%
Revenue Per Employee	1.30M
Profits Per Employee	158,170
Employee Count	5,270
Asset Turnover	0.24
Inventory Turnover	2.44

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -43.16% in the last 52 weeks. The beta is 0.81, so Luye Pharma Group's price volatility has been lower than the market average.

Beta (5Y)	0.81
52-Week Price Change	-43.16%
50-Day Moving Average	2.56
200-Day Moving Average	2.81
Relative Strength Index (RSI)	23.96
Average Volume (20 Days)	27,340,318

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Luye Pharma Group had revenue of HKD 6.78 billion and earned 827.86 million in profits. Earnings per share was 0.22.

Revenue	6.78B
Gross Profit	4.66B
Operating Income	1.38B
Pretax Income	1.08B
Net Income	827.86M
EBITDA	2.11B
EBIT	1.38B
Earnings Per Share (EPS)	0.22

Full Income Statement

Balance Sheet

The company has 6.96 billion in cash and 10.16 billion in debt, giving a net cash position of -3.19 billion or -0.85 per share.

Cash & Cash Equivalents	6.96B
Total Debt	10.16B
Net Cash	-3.19B
Net Cash Per Share	-0.85
Equity (Book Value)	15.13B
Book Value Per Share	3.72
Working Capital	2.97B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 549.45 million and capital expenditures -679.79 million, giving a free cash flow of -130.33 million.

Operating Cash Flow	549.45M
Capital Expenditures	-679.79M
Free Cash Flow	-130.33M
FCF Per Share	-0.03

Full Cash Flow Statement

Margins

Gross margin is 68.73%, with operating and profit margins of 20.35% and 12.20%.

Gross Margin	68.73%
Operating Margin	20.35%
Pretax Margin	15.86%
Profit Margin	12.20%
EBITDA Margin	31.17%
EBIT Margin	20.35%
FCF Margin	n/a

Dividends & Yields

Luye Pharma Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.81%
Shareholder Yield	-4.81%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Luye Pharma Group has an Altman Z-Score of 1.42. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.42
Piotroski F-Score	n/a